Clinical and endocrine characteristics of the main polycystic ovary syndrome phenotypes

Size: px
Start display at page:

Download "Clinical and endocrine characteristics of the main polycystic ovary syndrome phenotypes"

Transcription

1 POLYCYSTIC OVARY SYNDROME Clinical and endocrine characteristics of the main polycystic ovary syndrome phenotypes Ettore Guastella, M.D., a Rosa Alba Longo, M.D., b and Enrico Carmina, M.D. b a Department of Obstetrics and Gynecology, and b Department of Biomedical Sciences, University of Palermo, Palermo, Italy Objective: To evaluate the clinical and endocrine differences between main polycystic ovary syndrome (PCOS) phenotypes. Design: To evaluate clinical and hormone parameters in a large group of consecutive women with PCOS diagnosed according Rotterdam criteria and divided according their phenotype. Setting: University department of medicine. Patient(s): Three hundred eighty-two consecutive women with PCOS and 85 ovulatory controls. Intervention(s): Evaluation of clinical and hormone parameters. Main Outcome Measure(s): Blood levels of gonadotropins, testosterone, sex-hormone binding globulin, dehydroepiandrosterone sulfate, 17a-hydroxyprogesterone, progesterone, glucose, and insulin, and calculation of the free androgen index and insulin sensitivity. Result(s): The severe PCOS phenotype (hyperandrogenism, chronic anovulation, and polycystic ovaries: type I classic PCOS) was the most common phenotype in 53.9% of the patients. The phenotype of 8.9% of patients was characterized by hyperandrogenism and chronic anovulation but normal ovaries (type II classic PCOS). The two phenotypes of classic PCOS had similar clinical and endocrine characteristics, but the patients with polycystic ovaries had a higher luteinizing hormone/follicle-stimulating hormone (LH/FSH) ratio. Ovulatory PCOS was relatively common (28.8% of PCOS patients) and presented milder clinical and endocrine alterations than the classic PCOS phenotypes. The normoandrogenic phenotype was relatively uncommon. These patients had a normal body mass index, insulin sensitivity, and free androgen index but showed increased levels of LH and LH/FSH ratio. Conclusion(s): Ovulatory PCOS represents the mild form of classic PCOS, but the normoandrogenic phenotype, although part of the spectrum, may represent a different disorder or have a different pathogenetic pathway. (Fertil Steril Ò 2010;94: Ó2010 by American Society for Reproductive Medicine.) Key Words: PCOS, hyperandrogenism, anovulation Polycystic ovary syndrome is a very heterogeneous disorder that may include different phenotypes. For many years, only the classic phenotype of chronic anovulation and hyperandrogenism was included in the PCOS diagnosis (1). The Rotterdam criteria (2) are more extensive, including patients with very different clinical appearances. In fact, according to these guidelines, the diagnosis of PCOS may present in patients with four different phenotypes: [1] hyperandrogenism, chronic anovulation, and polycystic ovaries; [2] hyperandrogenism and chronic anovulation but normal ovaries; [3] hyperandrogenism and polycystic ovaries but ovulatory cycles; and [4] chronic anovulation and polycystic ovaries but no clinical or biochemical hyperandrogenism. An expert committee of the Androgen Excess and PCOS Society (AEPCOS) suggested including only the first three phenotypes, excluding the fourth from the PCOS spectrum (3). However, few studies have addressed the clinical and endocrine difference between Received November 10, 2009; revised February 2, 2010; accepted February 4, 2010; published online March 19, G.E. has nothing to disclose. L.R.A. has nothing to disclose. C.E. has nothing to disclose. Reprint requests: Enrico Carmina, M.D., Department of Biomedical Sciences, University of Palermo, Via delle Croci 47, Palermo, Italy (FAX: ; enricocarmina@libero.it). these phenotypes (4 6), and disagreement on the limits of the disorder persists. We previously analyzed the differences between classic (chronic anovulation and hyperandrogenism) and ovulatory PCOS (hyperandrogenism and polycystic ovaries but ovulatory cycles) (7) and found that patients with classic PCOS have a more severe form of the disorder but both phenotypes share the same alterations. In this study, we report on the relative prevalence in a medical setting and the clinical and endocrine characters of all four Rotterdam PCOS phenotypes. We studied 382 consecutive women in whom PCOS had been diagnosed according to the Rotterdam criteria (2). We classified them according to the four phenotypes, and analyzed the relative prevalence and the clinical and endocrine characteristics of each phenotype. A true prevalence study would survey a community, and the setting of our study (an endocrinology clinic) may have influenced the reported prevalence of different phenotypes. However, our department represents a regional reference center for women with all types of menstrual irregularities and/or clinical signs of androgen excess. MATERIALS AND METHODS Between 2004 and 2009, among the women referred to the endocrine unit of the Department of Clinical Medicine, University of Palermo, for clinical /$36.00 Fertility and Sterility â Vol. 94, No. 6, November doi: /j.fertnstert Copyright ª2010 American Society for Reproductive Medicine, Published by Elsevier Inc.

2 TABLE 1 Clinical data of 85 normal ovulatory controls and 382 PCOS patients divided according their phenotype. n Age (y) BMI Waist (cm) Ferriman-Gallwey scores Controls Type I classic PCOS (A, HA, PCO) a,b,c a,b,c a,b,c Type II classic PCOS (A, HA) a,b,c a,b,c a,b,c Ovulatory PCOS (HA, PCO) a,c 85 9 a,c a,c Normoandrogenic PCOS (A, PCO) Note: A ¼ anovulation (chronic); BMI ¼ body mass index; HA ¼ hyperandrogenism (clinical or biochemical); PCO ¼ polycystic ovaries; PCOS ¼ polycystic ovary syndrome. a P<.01 compared with controls. b P<.01 compared with ovulatory PCOS. c P<.01 compared with normoandrogenic PCOS. hyperandrogenism and/or menstrual irregularities, 382 consecutive women were found to have PCOS, diagnosed according to Rotterdam criteria (2). None of the patients enrolled in our study had taken any medications for at least 3 previous months. Our procedures were in agreement with the Helsinki Declaration of 1975 as revised in 1983, and the study was approved by the local ethics council. All participants gave their informed consent to participate to the study. Clinical hyperandrogenism was defined as presence of hirsutism, acne, or androgenic alopecia. Hirsutism was assessed by Ferriman-Gallwey- Lorenzo scores (8), and patients with scores R6 were considered hirsute; acne was graded by a scoring system from 0 to 3 (9), and alopecia was evaluated by the Ludwig scoring system (10). Menstrual cycles shorter than 25 days and longer than 34 days were considered abnormal. The clinical study included assessment of clinical hyperandrogenism, body mass index (BMI), age, waist circumference, and characteristics of the menstrual cycle. In all patients and in 85 normal ovulatory controls, the blood levels of luteinizing hormone (LH), follicle-stimulating hormone (FSH), testosterone (T), dehydroepiandrosterone sulfate (DHEAS), estradiol, sex-hormone binding globulin (SHBG), 17a-hydroxyprogesterone (17-OHP), progesterone, glucose, and insulin were measured. The free androgen index (FAI) was calculated (11), and insulin sensitivity was evaluated by the quantitative insulin-sensitivity check index (QUICKI) method (12). Concentrations of LH, FSH, estradiol, testosterone, SHBG, DHEAS, and 17-OHP were determined during the follicular phase (days 5 to 8) of a spontaneous or progestininduced cycle. Serum progesterone was determined on days 21 to 24 of a spontaneous or induced menstrual cycle. Serum insulin and blood glucose were measured in the fasting state, in the morning. Serum hormone levels were quantified by well-established methods validated previously in our laboratory. All steroids were measured by specific radioimmunoassay (RIA) after extraction by use of methods previously described elsewhere (13). In all assays, the intra-assay and interassay coefficients of variation did not exceed 6% and 15%, respectively. In some patients, clinical suspicion also prompted measurement of urinary free cortisol, serum prolactin, and thyroid-stimulating hormone by commercial RIA methods. Anovulation was defined as serum progesterone <3 ng/ml (<9.54 nmol/ L). In patients with normal menses, at least two consecutive menstrual cycles were studied and a finding of low levels of serum progesterone (<3 ng/ml) in both cycles indicated the presence of chronic anovulation. Biochemical hyperandrogenism was defined as serum testosterone >60 ng/dl (>2.08 nmol/ L) and/or serum DHEAS R3 mg/ml (R7.8 mmol/l) and/or FAI R4. These values of hyperandrogenism had been previously calculated in our population by use of the same assays (14). Increased serum 17-OHP was defined as serum 17-OHP >3 mg/l (>9.1 nmol/l). In patients with mildly increased serum 17-OHP (<10 mg/l to >3 mg/l), increased 17-OHP response to adrenocorticotropic hormone (ACTH) administration (1 mg IV with blood samples at 0, 30, and 60 minutes) was required for diagnosis of nonclassic 21-hydroxylase deficiency (15). In all patients and controls, ovarian morphologic features were assessed by pelvic ultrasound. Ovarian size (by measurement of the main three ovarian diameters in both ovaries), and the presence, size, and number of ovarian microcysts were determined. The data obtained by abdominal and transvaginal ultrasounds were considered useful for the diagnosis. Polycystic ovaries were established by the presence of 10 or more peripherally oriented cystic structures in one ultrasonographic plane, each of which measured 2 to 10 mm in diameter, arranged around a dense stroma (16, 17). Ovarian volume was calculated by the formula p/6 (D 1 D 2 D 3 ), where the dimensions (D) of length, width, and thickness were used. The size of both ovaries was assessed, and the mean ovarian size was calculated. According to our data on normal women, increased ovarian size indicates that the mean ovarian size is larger than 7.5 cc 3 (17). The women with PCOS diagnosed according to Rotterdam criteria (2) were divided in four different phenotypes: [1] hyperandrogenism, chronic anovulation, and polycystic ovaries; [2] hyperandrogenism and chronic anovulation but normal ovaries; [3] hyperandrogenism and polycystic ovaries but ovulatory cycles; or [4] chronic anovulation and polycystic ovaries but no clinical or biochemical hyperandrogenism. The following arbitrary names were assigned to these phenotypes, respectively: [1] type I classic PCOS; [2] type II classic PCOS; [3] ovulatory PCOS; and [4] normoandrogenic PCOS. Statistical Analysis Group means were compared using analysis of variance (ANOVA) with post hoc least squares means pair wise comparisons (after log transformation of the values). All data are presented as mean standard deviation (SD). RESULTS Relative Prevalence of Different PCOS Phenotypes Of the study participants, 206 patients (53.9%) presented with all characteristics of the Rotterdam guidelines: hyperandrogenism, chronic anovulation, and polycystic ovaries (type I classic PCOS). Thirty-four patients (8.9%) exhibited hyperandrogenism and chronic anovulation but normal ovaries (type II classic PCOS). In total, 240 patients (62.8%) had PCOS according to U.S. National Institutes of Health criteria (1). We found that 110 patients (28.8%) presented with hyperandrogenism and polycystic ovaries but normal ovulatory cycles (ovulatory PCOS). In total, 350 patients (91.6%) had PCOS according AEPCOS guidelines (3). Finally, 32 patients (8.4%) presented chronic anovulation and polycystic ovaries but showed no clinical or biologic signs of hyperandrogenism (normoandrogenic PCOS) Guastella et al. PCOS phenotypes Vol. 94, No. 6, November 2010

3 TABLE 2 Concentrations of LH, LH/FSH ratio, and androgens in 85 normal ovulatory controls and 382 PCOS patients divided according their phenotype. LH (miu/ml) LH/FSH ratio T (ng/dl) SHBG (nmol/l) FAI DHEAS (mg/ml) Controls Type I classic PCOS (A, HA, PCO) a,b,c a,b,c a,b,d a,b,d a,b,d a,d Type II classic PCOS (A, HA) a,b a,b,d a,b,d a,b,d a,d Ovulatory PCOS (HA, PCO) a,d a,b a,d a,d Normoandrogenic PCOS (A, PCO) a,b,c a,b a Note: A ¼ anovulation (chronic); HA ¼ hyperandrogenism (clinical or biochemical); DHEAS ¼ dehydroepiandrosterone sulfate; FAI ¼ free androgen index; FSH ¼ follicle-stimulating hormone; LH ¼ luteinizing hormone; PCO ¼ polycystic ovaries; PCOS ¼ polycystic ovary syndrome; SHBG ¼ sex-hormone binding globulin; T, testosterone. a P<.01 versus controls. b P<.01 versus ovulatory PCOS. c P<.01 versus type II classic PCOS. d P<.01 versus normoandrogenic PCOS. Clinical and Endocrine Characters of Different PCOS Phenotypes No difference in age was observed between the different PCOS phenotypes (Table 1). Patients with both type I and type II classic PCOS had statistically significantly (P<.01) higher values for BMI, waist circumference, Ferriman-Gallwey-Lorenzo scores, levels of testosterone, FAI, and insulin, and lower QUICKI values than the controls and the patients with ovulatory or normoandrogenic PCOS (Tables 1, 2, and 3). Both phenotypes had also statistically significantly (P<.01) higher DHEAS values than the controls and women with normoandrogenic PCOS (see Table 2). The two phenotypes of classic PCOS differed only in LH and LH/FSH ratios, which were statistically significantly higher in type I than in type II classic PCOS (see Table 2). Type I classic PCOS had statistically significantly higher values for LH levels and LH/FSH ratio than the controls and patients with ovulatory PCOS (see Table 2). Patients with type II classic PCOS had LH values that were similar to the controls and patients with ovulatory PCOS but a higher LH/FSH ratio than those two groups (see Table 2). Patients with ovulatory PCOS had statistically significantly higher values for BMI, waist circumference, Ferriman-Gallwey- Lorenzo score, levels of testosterone, FAI, DHEAS, and insulin, and lower QUICKI values than controls and patients with normoandrogenic PCOS (see Tables 1, 2, and 3). Patients with ovulatory PCOS had LH and LH/FSH ratios similar to normal controls but lower than patients with classic or normoandrogenic PCOS (see Table 2). In spite of the differences in LH concentration, all of the PCOS phenotypes had similar levels of estradiol. Finally, patients with normoandrogenic PCOS had statistically significantly higher values for LH and the LH/FSH ratio than the controls (see Table 2). Also, although their testosterone values were in the normal range, their mean testosterone was statistically significantly higher compared with controls (see Table 2). However, there was no statistically significant difference between patients with normoandrogenic PCOS and controls in terms of concentrations of SHBG, FAI, or DHEAS (see Table 2). Normoandrogenic PCOS patients and controls had also similar BMI, waist circumference, Ferriman-Gallwey-Lorenzo scores, levels of DHEAS and insulin, and QUICKI (see Tables 1, 2, and 3). DISCUSSION After evaluation of a sufficiently large number of consecutive women with a diagnosis of PCOS according to the Rotterdam criteria (2), our study provides information on the relative prevalence in TABLE 3 Insulin, insulin sensitivity, and ovarian volume in 85 normal ovulatory controls and 382 PCOS women divided according their phenotype. Insulin (miu/ml) QUICKI Ovarian volume (cm 3 ) Controls Type I classic PCOS (A, HA, PCO) a,b,c a,b,c a,d Type II classic PCOS (A, HA) a,b,c a,b,c Ovulatory PCOS (HA, PCO) a,c a,c 11 4 a,d Normoandrogenic PCOS (A, PCO) a,d Note: A ¼ anovulation (chronic); HA ¼ hyperandrogenism (clinical or biochemical); PCO ¼ polycystic ovaries; PCOS ¼ polycystic ovary syndrome; QUICKI ¼ quantitative insulin-sensitivity check index. a P<.01 versus controls. b P<.01 versus ovulatory PCOS. c P<.01 versus normoandrogenic PCOS. d P<.01 versus type II classic PCOS. Fertility and Sterility â 2199

4 a medical setting and the clinical and endocrine differences among the main PCOS phenotypes, as determined according Rotterdam criteria (2). These diagnostic guidelines (2) have included in the PCOS group four different phenotypes. The names we have given to these phenotypes (type I and type II classic PCOS, ovulatory PCOS, normoandrogenic PCOS) may be arbitrary and not accepted by all experts, but they reflect the main characteristics of the different phenotypes. For a long time, the diagnosis of PCOS was based only on chronic anovulation and hyperandrogenism (1), and we have classified these patients as classic PCOS, differentiating between type I and type II depending on the finding of polycystic ovaries. The other phenotypes are characterized by the finding of normal ovulation in spite of hyperandrogenism and polycystic ovaries and by the absence of clinical or biochemical hyperandrogenism in spite of chronic anovulation and polycystic ovaries. Although the Rotterdam criteria have been accepted by many experts, almost no information was available regarding the differences between the included phenotypes at the time the criteria were created. In particular, there were no data on normoandrogenic PCOS or on patients with classic PCOS but normal ovaries (the phenotype that we have defined as type II classic PCOS). Thus, the Androgen Excess and PCOS Society has suggested not including patients with normal androgen levels among the PCOS phenotypes (3). More recently, Dewailly and al. (4) reported that patients with chronic anovulation and polycystic ovaries but normal androgens have higher values of testosterone than controls, which suggests that these patients have a mild form of androgen excess. Welt et al. (5), studying a large heterogeneous group that included patients from New England and Iceland, concluded that ovulatory and normoandrogenic PCOS both represent a mild form of PCOS. In fact, they observed that these patients presented similar but milder abnormalities compared with patients with PCOS as diagnosed according U.S. National Institutes of Health criteria (5). Our study has the advantage of evaluating a large, homogenous group of patients under the same environmental conditions. Although we used a slightly different, U.S. variation on the Rotterdam criteria (16), it should be noted that some of the authors of Rotterdam guidelines also have corrected their definition of increased ovarian volume and use the limit of 7.5 cc (the same that we use) (18). 1. Type I classic PCOS represents the most common and severe form of PCOS. These patients presented as group with abdominal obesity, increased levels of LH and LH/FSH ratio, increased androgens, and elevated insulin and insulin resistance. In our setting, these patients represented almost 60% of all PCOS patients. 2. Type II classic PCOS patients are very similar to other classic PCOS patients, but they are less common (only 8.4% of the total number of PCOS patients). The main difference between type I and type II classic PCOS is the LH levels and LH/FSH ratio. All patients with classic PCOS have increased LH and LH/ FSH ratios when compared with controls, but patients with polycystic ovaries have statistically significantly higher LH levels (and LH/FSH ratios) than patients with normal ovaries. This suggests that LH is important or in some way is related to the morphologic appearance of the ovaries. 3. Ovulatory PCOS seems to be the mild form of classic PCOS. These patients presented with the most characteristics of PCOS but in a milder form. In fact, patients with ovulatory PCOS had intermediate values (between classic PCOS and controls) of BMI, waist circumference, testosterone, insulin, and QUICKI. Only the LH level was generally normal, and it represents the main difference from the other phenotypes of PCOS. On the other hand, it is well known that many patients with classic PCOS can attain ovulation by reducing their body weight (19). Therefore, we suggest that ovulatory PCOS may be the mild form of classic PCOS. Passage from classic to ovulatory PCOS and vice versa may be possible and related to sociocultural and environmental influences (20, 21). 4. Normoandrogenic PCOS represents a unique group. We have confirmed the report by Dewailly et al. (4) that these patients have a mild testosterone excess (although within the normal range), but these patients do not present with hyperandrogenism in fact, both their FAI and DHEAS levels are normal. Nor do these patients present with abdominal obesity they have a normal BMI and normal waist circumference. From an endocrine point of view, this group of women is mainly characterized by increased LH and LH/FSH ratio, which is similar to classic PCOS and may be related in some way to their anovulation. In our opinion, normoandrogenic PCOS is part of the PCOS spectrum but may be a different disorder or have a different pathogenetic pathway. These women do not exhibit the two main components of PCOS: hyperandrogenism (at least, clinically relevant hyperandrogenism) and insulin resistance. Thus, we believe that it would be correct to keep these patients separated from other PCOS patients, as suggested by the Androgen Excess and PCOS Society committee (3). The different phenotypes of PCOS present similarities but also important differences in their clinical and endocrine pattern, and research studies should keep these differences in mind. We suggest that, although the Rotterdam criteria may be useful for understanding the complexity and the heterogeneity of the syndrome, it is important that patients are well characterized according to their phenotype. Patients with completely different phenotypes and clinical and endocrine patterns should not be indiscriminately grouped together. This is particularly important for patients with normoandrogenic PCOS, who may develop PCOS by a different pathogenetic pathway or have a different disorder. REFERENCES 1. Zawadzki JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rationale approach. In: Dunaif A, Givens JR, Haseltine F, Merriam GR, eds. Polycystic ovary syndrome. Boston: Blackwell Scientific, 1992: Rotterdam ESHRE/ASRM Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81: Azziz R, Carmina E, Dewailly D, Diamanti- Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. Position statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an androgen excess society guideline. J Clin Endocrinol Metab 2006;91: Dewailly D, Catteau-Jonard S, Reyss AC, Leroy M, Pigny P. Oligoanovulation with polycystic ovaries but not overt hyperandrogenism. J Clin Endocrinol Metab 2006;91: Welt CK, Gudmundsson JA, Arsson G, Adams J, Palsdottir H, Gudlaugsdottir G, et al. Characterizing discrete subsets of polycystic ovary syndrome as defined by the Rotterdam criteria: the impact of weight on phenotype and metabolic features. J Clin Endocrinol Metab 2006;91: Barber TM, Wass JA, McCarthy MI, Franks S. Metabolic characteristics of women with polycystic ovaries and oligo-amenorrhoea but normal androgen levels: implications for the management of polycystic ovary syndrome. Clin Endocrinol (Oxf) 2007;66: Carmina E. The spectrum of androgen excess disorders. Fertil Steril 2006;85: Hatch R, Rosenfield RL, Kim MH, Tredway D. Hirsutism: implications, etiology and management. Am J Obstet Gynecol 1981;140: Guastella et al. PCOS phenotypes Vol. 94, No. 6, November 2010

5 9. Lookingbill DP, Egan N, Santen RJ, Demers LM. Correlation of serum 3a-androstanediol glucuronide with acne and chest hair density in men. J Clin Endocrinol Metab 1988;67: Ludwig E. Classification of the types of androgenic alopecia (common balding occurring in the female sex). Br J Dermatol 1977;97: Morley JE, Patrick P, Perry HM III. Evaluation of assays available to measure free testosterone. Metabolism 2002;51: Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, Quon MJ. Quantitative insulin sensitivity check index: a simple, accurate method of assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000;85: Carmina E, Stanczyk F, Chang L, Miles RA, Lobo RA. The ratio of androstenedione: 11b-hydroxyandrostenedione is an important marker of adrenal androgen excess in women. Fertil Steril 1992;58: Carmina E. Prevalence of idiopathic hirsutism. Eur J Endocrinol 1998;139: Carmina E, Lobo RA. Ovarian suppression reduces clinical and endocrine expression of late onset congenital adrenal hyperplasia due to 21- hydroxylase deficiency. Fertil Steril 1994;62: Balen AH, Laven JS, Tan SL, Dewailly D. Ultrasound assessment of the polycystic ovary: international consensus definitions. Hum Reprod Update 2003;9: Carmina E, Orio F, Palomba S, Longo RA, Lombardi G, Lobo RA. Ovarian size and blood flow in women with polycystic ovary syndrome (PCOS) and their correlations with some endocrine parameters. Fertil Steril 2005;84: Jonard S, Robert Y, Dewailly D. Revisiting the ovarian volume as a diagnostic criterion for polycystic ovaries. Hum Reprod 2005;20: Huber-Buckholz MM, Carey DG, Norman RJ. Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone. J Clin Endocrinol Metab 1999;84: Carmina E, Legro RS, Stamets K, Lowell J, Lobo RA. Difference in body weight between American and Italian women with polycystic ovary syndrome: influence of the diet. Hum Reprod 2003;11: Di Fede G, Mansueto P, Longo RA, Rini G, Carmina E. Influence of sociocultural factors on the ovulatory status of polycystic ovary syndrome. Fertil Steril 2009;91: Fertility and Sterility â 2201

X/06/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 91(1):2 6 Copyright 2006 by The Endocrine Society doi: /jc.

X/06/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 91(1):2 6 Copyright 2006 by The Endocrine Society doi: /jc. 0021-972X/06/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 91(1):2 6 Printed in U.S.A. Copyright 2006 by The Endocrine Society doi: 10.1210/jc.2005-1457 EXTENSIVE CLINICAL EXPERIENCE Relative

More information

METABOLIC RISK MARKERS IN WOMEN WITH POLYCYSTIC OVARIAN MORPHOLOGY

METABOLIC RISK MARKERS IN WOMEN WITH POLYCYSTIC OVARIAN MORPHOLOGY Vuk Vrhovac University Clinic Dugi dol 4a, HR-10000 Zagreb, Croatia Original Research Article Received: February 18, 2010 Accepted: March 3, 2010 METABOLIC RISK MARKERS IN WOMEN WITH POLYCYSTIC OVARIAN

More information

Insulin resistance and endocrine characteristics of the different phenotypes of polycystic ovary syndrome: a prospective study

Insulin resistance and endocrine characteristics of the different phenotypes of polycystic ovary syndrome: a prospective study Human Reproduction, Vol.0, No.0 pp. 1 9, 2011 doi:10.1093/humrep/der418 Hum. Reprod. Advance Access published December 5, 2011 ORIGINAL ARTICLE Reproductive endocrinology Insulin resistance and endocrine

More information

Polycystic Ovary Syndrome HEATHER BURKS, MD OU PHYSICIANS REPRODUCTIVE MEDICINE SEPTEMBER 21, 2018

Polycystic Ovary Syndrome HEATHER BURKS, MD OU PHYSICIANS REPRODUCTIVE MEDICINE SEPTEMBER 21, 2018 Polycystic Ovary Syndrome HEATHER BURKS, MD OU PHYSICIANS REPRODUCTIVE MEDICINE SEPTEMBER 21, 2018 Learning Objectives At the conclusion of this lecture, learners should: 1) Know the various diagnostic

More information

Investigation of adrenal functions in patients with idiopathic hyperandrogenemia

Investigation of adrenal functions in patients with idiopathic hyperandrogenemia European Journal of Endocrinology (26) 155 37 311 ISSN 84-4643 CLINICAL STUDY Investigation of adrenal functions in patients with idiopathic hyperandrogenemia Hulusi Atmaca, Fatih Tanriverdi 1, Kursad

More information

Clinical and biochemical characteristics of polycystic ovary syndrome in Korean women

Clinical and biochemical characteristics of polycystic ovary syndrome in Korean women Human Reproduction Vol.23, No.8 pp. 1924 1931, 2008 Advance Access publication on June 24, 2008 doi:10.1093/humrep/den239 Clinical and biochemical characteristics of polycystic ovary syndrome in Korean

More information

European Journal of Endocrinology (2006) ISSN

European Journal of Endocrinology (2006) ISSN European Journal of Endocrinology (2006) 154 141 145 ISSN 0804-4643 CLINICAL STUDY Metabolic syndrome in polycystic ovary syndrome (PCOS): lower prevalence in southern Italy than in the USA and the influence

More information

ROLE OF HORMONAL ASSAY IN DIAGNOSING PCOD DR GAANA SREENIVAS (JSS,MYSURU)

ROLE OF HORMONAL ASSAY IN DIAGNOSING PCOD DR GAANA SREENIVAS (JSS,MYSURU) ROLE OF HORMONAL ASSAY IN DIAGNOSING PCOD DR GAANA SREENIVAS (JSS,MYSURU) In 1935, Stein and Leventhal described 7 women with bilateral enlarged PCO, amenorrhea or irregular menses, infertility and masculinizing

More information

Nitasha Garg 1 Harkiran Kaur Khaira. About the Author

Nitasha Garg 1 Harkiran Kaur Khaira. About the Author https://doi.org/10.1007/s13224-017-1082-4 ORIGINAL ARTICLE A Comparative Study on Quantitative Assessment of Blood Flow and Vascularization in Polycystic Ovary Syndrome Patients and Normal Women Using

More information

Case Questions. Polycystic Ovarian Syndrome: Treatment Goals and Options. Differential Diagnosis of Hyperandrogenic Anovulation

Case Questions. Polycystic Ovarian Syndrome: Treatment Goals and Options. Differential Diagnosis of Hyperandrogenic Anovulation Polycystic Ovarian Syndrome: Treatment Goals and Options Marc Cornier, MD Division of Endocrinology, Metabolism and Diabetes Colorado Center for Health and Wellness University of Colorado School of Medicine

More information

Characteristics of different phenotypes of polycystic ovary syndrome based on the Rotterdam criteria in a large-scale Chinese population

Characteristics of different phenotypes of polycystic ovary syndrome based on the Rotterdam criteria in a large-scale Chinese population DOI: 10.1111/j.1471-0528.2009.02347.x www.bjog.org Fertility and assisted reproduction Characteristics of different phenotypes of polycystic ovary syndrome based on the Rotterdam criteria in a large-scale

More information

The prevalence of polycystic ovary syndrome in Iranian women based on different diagnostic criteria

The prevalence of polycystic ovary syndrome in Iranian women based on different diagnostic criteria Prace oryginalne/original papers Endokrynologia Polska/Polish Journal of Endocrinology Tom/Volume 62; Numer/Number 3/2011 ISSN 0423 104X The prevalence of polycystic ovary syndrome in Iranian women based

More information

Gynecology-endocrinology

Gynecology-endocrinology Gynecology-endocrinology FERTILITY AND STERILITY Copyright (fj 1991 The American Fertility Society Vol. 55, No, 5, May 1991 Printed on acid-free paper in U.S.A. Serum androsterone conjugates differentiate

More information

Polycystic Ovary Syndrome (PCOS):

Polycystic Ovary Syndrome (PCOS): Polycystic Ovary Syndrome (PCOS): Current diagnosis and treatment Anatte E. Karmon, MD Disclosures- Anatte Karmon, MD No financial relationships to disclose 2 Objectives At the end of this presentation,

More information

Salivary Versus Serum Approaches in Assessment of Biochemical Hyperandrogenemia

Salivary Versus Serum Approaches in Assessment of Biochemical Hyperandrogenemia Original Article Salivary Versus Serum Approaches in Assessment of Biochemical Hyperandrogenemia Mohamed Nabih El Gharib, Sahar Mohey El Din Hazaa 1 Departments of Obstetrics and Gynecology, and 1 Clinical

More information

Polycystic Ovarian Syndrome: Diagnosis, Preconceptional Management and Health Risks

Polycystic Ovarian Syndrome: Diagnosis, Preconceptional Management and Health Risks Polycystic Ovarian Syndrome: Diagnosis, Preconceptional Management and Health Risks Kate D. Schoyer, M.D. May 6, 2016 Objectives To review how to make the diagnosis of Polycystic Ovarian Syndrome (PCOS)

More information

Determining the insulin resistance rate in Polycystic Ovary Syndrome patients (PCOs)

Determining the insulin resistance rate in Polycystic Ovary Syndrome patients (PCOs) Abstract: Determining the insulin resistance rate in Polycystic Ovary Syndrome patients (PCOs) Ashraf Olabi, Ghena Alqotini College of medicine, Aleppo University Hospital Obstetrics and Gynacology, Syria.

More information

Polycystic Ovarian Syndrome (PCOS) LOGO

Polycystic Ovarian Syndrome (PCOS) LOGO Polycystic Ovarian Syndrome (PCOS) Ma qianhong Ob/Gyn Department LOGO Contents Epidemiology and Definition Pathophysiology, Endocrinological Features Diagnostic Criteria Treatment Prognosis Introduction

More information

Prevalence of polycystic ovarian syndrome in the Buraimi region of Oman

Prevalence of polycystic ovarian syndrome in the Buraimi region of Oman Original Article Brunei Int Med J. 2012; 8 (5): 248-252 Prevalence of polycystic ovarian syndrome in the Buraimi region of Oman Usha VARGHESE 1 and Shaji VARUGHESE 2, 1 Department of Internal Medicine

More information

12/13/2017. Important references for PCOS. Polycystic Ovarian Syndrome (PCOS) for the Family Physician. 35 year old obese woman

12/13/2017. Important references for PCOS. Polycystic Ovarian Syndrome (PCOS) for the Family Physician. 35 year old obese woman Polycystic Ovarian Syndrome (PCOS) for the Family Physician Barbara S. Apgar MD, MS Professor or Family Medicine University of Michigan Ann Arbor, Michigan Important references for PCOS Endocrine Society

More information

Hirsutism: Diagnosis and Treatment. Roger A. Lobo M.D. Columbia University

Hirsutism: Diagnosis and Treatment. Roger A. Lobo M.D. Columbia University Hirsutism: Diagnosis and Treatment Roger A. Lobo M.D. Columbia University Signs of hyperandrogenism Acne, Hirsutism, Alopecia All explained by increased androgen production and/or increased sensitivity

More information

Idiopathic hirsutism: an uncommon cause of hirsutism in Alabama

Idiopathic hirsutism: an uncommon cause of hirsutism in Alabama FERTILITY AND STERILITY VOL. 70, NO. 2, AUGUST 1998 Copyright 1998 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Idiopathic hirsutism:

More information

Polycystic ovarian syndrome: Are radiology departments contributing to the misdiagnosis?

Polycystic ovarian syndrome: Are radiology departments contributing to the misdiagnosis? Polycystic ovarian syndrome: Are radiology departments contributing to the misdiagnosis? Poster No.: C-1238 Congress: ECR 2010 Type: Scientific Exhibit Topic: Genitourinary Authors: G. Tony, N. V. Gurjar,

More information

Overview of Reproductive Endocrinology

Overview of Reproductive Endocrinology Overview of Reproductive Endocrinology I have no conflicts of interest to report. Maria Yialamas, MD Female Hypothalamic--Gonadal Axis 15 4 Hormone Secretion in the Normal Menstrual Cycle LH FSH E2, Progesterone,

More information

Polycystic Ovarian Syndrome: Diagnosis, Preconceptional Management and Health Risks. Kate D. Schoyer, M.D. May 6, 2016

Polycystic Ovarian Syndrome: Diagnosis, Preconceptional Management and Health Risks. Kate D. Schoyer, M.D. May 6, 2016 Polycystic Ovarian Syndrome: Diagnosis, Preconceptional Management and Health Risks Kate D. Schoyer, M.D. May 6, 2016 Objectives To review how to make the diagnosis of Polycystic Ovarian Syndrome (PCOS)

More information

S. AMH in PCOS Research Insights beyond a Diagnostic Marker

S. AMH in PCOS Research Insights beyond a Diagnostic Marker S. AMH in PCOS Research Insights beyond a Diagnostic Marker Dr. Anushree D. Patil, MD. DGO Scientist - D National Institute for Research in Reproductive Health (Indian Council of Medical Research) (Dr.

More information

Introduction. Original Article

Introduction. Original Article Iran J Reprod Med Vol. 10. No. 4. pp: 307-314, July 2012 Original Article Correlation of biochemical markers and clinical signs of hyperandrogenism in women with polycystic ovary syndrome (PCOS) and women

More information

Can Sex hormone Binding Globulin Considered as a Predictor of Response to Pharmacological Treatment in Women with Polycystic Ovary Syndrome?

Can Sex hormone Binding Globulin Considered as a Predictor of Response to Pharmacological Treatment in Women with Polycystic Ovary Syndrome? www.ijpm.in www.ijpm.ir Can Sex hormone Binding Globulin Considered as a Predictor of Response to Pharmacological Treatment in Women with Polycystic Ovary Syndrome? Ferdous Mehrabian, Maryam Afghahi Department

More information

Thomas M. Barber*, John A. H. Wass*, Mark I. McCarthy* and Stephen Franks

Thomas M. Barber*, John A. H. Wass*, Mark I. McCarthy* and Stephen Franks Clinical Endocrinology (2007) 66, 513 517 doi: 10.1111/j.1365-2265.2007.02764.x ORIGINAL ARTICLE Blackwell Publishing Ltd Metabolic characteristics of women with polycystic ovaries and oligo-amenorrhoea

More information

Polycystic Ovary Syndrome

Polycystic Ovary Syndrome Polycystic Ovary Syndrome Definition: the diagnostic criteria Evidence of hyperandrogenism, biochemical &/or clinical (hirsutism, acne & male pattern baldness). Ovulatory dysfunction; amenorrhoea; oligomenorrhoea

More information

Outlook PCOS: a diagnostic challenge

Outlook PCOS: a diagnostic challenge RBMOnline - Vol 8. No 6. 2004 644-648 Reproductive BioMedicine Online; www.rbmonline.com/article/1274 on web 5 April 2004 Outlook PCOS: a diagnostic challenge Dr Ricardo Azziz Dr Azziz is currently Chairman

More information

Amenorrhoea: polycystic ovary syndrome

Amenorrhoea: polycystic ovary syndrome There is so much we don't know in medicine that could make a difference, and often we focus on the big things, and the little things get forgotten. To highlight some smaller but important issues, we've

More information

Clinical Profile Polycystic Ovarian Syndrome Cases

Clinical Profile Polycystic Ovarian Syndrome Cases ORIGINAL RESEARCH www.ijcmr.com - 100 Cases Himabindu Sangabathula 1, Neelima Varaganti 1 ABSTRACT Introduction: Polycystic ovary syndrome (PCOS) is most common endocrine disorders of reproductive age

More information

Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc)

Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Guideline for the Investigation and Management of Polycystic Ovary Syndrome Author: Contact Name and Job Title

More information

Polycystic ovary syndrome. Phenotypic comparison of Caucasian and Asian women with polycystic ovary syndrome: a cross-sectional study

Polycystic ovary syndrome. Phenotypic comparison of Caucasian and Asian women with polycystic ovary syndrome: a cross-sectional study henotypic comparison of and women with polycystic ovary syndrome: a cross-sectional study Erica T. Wang, M.D., M.A.S., a Chia-Ning Kao, M.S., b Kanade Shinkai, M.D., h.d., c Lauri asch, h.d., d Marcelle

More information

The contributions of oestrogen and growth factors to increased adrenal androgen secretion in polycystic ovary syndrome

The contributions of oestrogen and growth factors to increased adrenal androgen secretion in polycystic ovary syndrome Human Reproduction vol.14 no.2 pp.307 311, 1999 The contributions of oestrogen and growth factors to increased adrenal androgen secretion in polycystic ovary syndrome E.Carmina 1, F.Gonzalez 2, A.Vidali

More information

Original Investigation. 94 Endocrine Oncology and Metabolism. Jovanovska et al

Original Investigation. 94 Endocrine Oncology and Metabolism. Jovanovska et al Original Investigation Sensitivity and specificity of anti-mülerian hormone in the diagnosis of polycystic ovary syndrome in a macedonian population of women of reproductive age: a cross-sectional study

More information

Polycystic Ovary Syndrome

Polycystic Ovary Syndrome Polycystic Ovary Syndrome Kathleen Colleran, MD Professor of Medicine University of New Mexico HSC Presented for COMM-TC May 4, 2012 Objectives Understand the pathophysiology of PCOS Understand how to

More information

POLYCYSTIC OVARY SYNDROME (PCOS) is a genetically

POLYCYSTIC OVARY SYNDROME (PCOS) is a genetically 0021-972X/04/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 89(6):2745 2749 Printed in U.S.A. Copyright 2004 by The Endocrine Society doi: 10.1210/jc.2003-032046 The Prevalence and Features

More information

DEFINING THE POLYCYSTIC ovary syndrome (PCOS)

DEFINING THE POLYCYSTIC ovary syndrome (PCOS) 0021-972X/06/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 91(10):3922 3927 Printed in U.S.A. Copyright 2006 by The Endocrine Society doi: 10.1210/jc.2006-1054 Oligoanovulation with Polycystic

More information

Endocrine abnormalities in ovulatory women with polycystic ovaries on ultrasound

Endocrine abnormalities in ovulatory women with polycystic ovaries on ultrasound Human Reproduction vol.12 no.5 pp. 905 909, 1997 Endocrine abnormalities in ovulatory women with polycystic ovaries on ultrasound E.Carmina 1, L.Wong 2, L.Chang 2, R.J.Paulson 2, disturbance of the IGF/IGFBP-l

More information

C. K. Welt,* J. A. Gudmundsson,* G. Arason,* J. Adams, H. Palsdottir, G. Gudlaugsdottir, G. Ingadottir, and W. F. Crowley

C. K. Welt,* J. A. Gudmundsson,* G. Arason,* J. Adams, H. Palsdottir, G. Gudlaugsdottir, G. Ingadottir, and W. F. Crowley 0021-972X/06/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 91(12):4842 4848 Printed in U.S.A. Copyright 2006 by The Endocrine Society doi: 10.1210/jc.2006-1327 Characterizing Discrete Subsets

More information

Antim ullerian hormone and polycystic ovary syndrome

Antim ullerian hormone and polycystic ovary syndrome Antim ullerian hormone and polycystic ovary syndrome Yi-Hui Lin, M.D., a Wan-Chun Chiu, Ph.D., c Chien-Hua Wu, Ph.D., b,e Chii-Ruey Tzeng, M.D., d Chun-Sen Hsu, M.D., a and Ming-I Hsu, M.D. a a Department

More information

JMSCR Vol 05 Issue 05 Page May 2017

JMSCR Vol 05 Issue 05 Page May 2017 www.jmscr.igmpublication.org Impact Factor 5.84 Index Copernicus Value: 83.27 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v5i5.14 Hyperinsulinemia in Polycystic Ovary Syndrome

More information

Ovarian Volume in Korean Women with Polycystic Ovary Syndrome and Its Related Factors

Ovarian Volume in Korean Women with Polycystic Ovary Syndrome and Its Related Factors pissn: 2288-6478, eissn: 2288-6761 Original Article Ovarian Volume in Korean Women with Polycystic Ovary Syndrome and Its Related Factors Young Shin Han 1, Ah Rha Lee 1, Hee Kyoung Song 1, Jeong In Choi

More information

What every dermatologist should know about Polycystic Ovary Syndrome (PCOS)

What every dermatologist should know about Polycystic Ovary Syndrome (PCOS) What every dermatologist should know about Polycystic Ovary Syndrome (PCOS) Kanade Shinkai, MD PhD University of California, San Francisco Associate Professor of Dermatology I have no conflicts of interest

More information

Diagnostic Performance of Serum Total Testosterone for Japanese Patients with Polycystic Ovary Syndrome

Diagnostic Performance of Serum Total Testosterone for Japanese Patients with Polycystic Ovary Syndrome Endocrine Journal 2007, 54 (2), 233 238 Diagnostic Performance of Serum Total Testosterone for Japanese Patients with Polycystic Ovary Syndrome TAKESHI IWASA, TOSHIYA MATSUZAKI, MASAHIRO MINAKUCHI, NAOKO

More information

metabolic characteristics of the polycystic ovary syndrome

metabolic characteristics of the polycystic ovary syndrome Page 1 of 32 Accepted Preprint first posted on 29 October 2012 as Manuscript EJE-12-0655 1 1 2 Association between menstrual cycle irregularities and endocrine and metabolic characteristics of the polycystic

More information

3. Metformin therapy for PCOS

3. Metformin therapy for PCOS 1. Introduction The key clinical features of polycystic ovary syndrome (PCOS) are hyperandrogenism (hirsutism, acne, alopecia) and menstrual irregularity with associated anovulatory infertility. 1 The

More information

WHY NEW DIAGNOSTIC CRITERIA FOR DIFFERENT PCOS PHENOTYPES ARE URGENTLY NEEDED

WHY NEW DIAGNOSTIC CRITERIA FOR DIFFERENT PCOS PHENOTYPES ARE URGENTLY NEEDED WHY NEW DIAGNOSTIC CRITERIA FOR DIFFERENT PCOS PHENOTYPES ARE URGENTLY NEEDED Ricardo Azziz, M.D., M.P.H., M.B.A. Chief Officer of Academic Health & Hospital Affairs State University of New York (SUNY)

More information

The Severity of Menstrual Dysfunction as a Predictor of Insulin Resistance in PCOS

The Severity of Menstrual Dysfunction as a Predictor of Insulin Resistance in PCOS JCEM ONLINE Brief Report Endocrine Research The Severity of Menstrual Dysfunction as a Predictor of Insulin Resistance in PCOS Meredith Brower, Kathleen Brennan, Marita Pall, and Ricardo Azziz Department

More information

Original Article Diagnostic value of prostate-specific antigen in women with polycystic ovary syndrome *

Original Article Diagnostic value of prostate-specific antigen in women with polycystic ovary syndrome * Received: 17.1.2011 Accepted: 24.7.2011 Original Article Diagnostic value of prostate-specific antigen in women with polycystic ovary syndrome * Farahnaz Mardanian 1, Nasrin Heidari 2 Abstract BACKGROUND:

More information

Racial influence on the polycystic ovary syndrome phenotype: a black and white case-control study

Racial influence on the polycystic ovary syndrome phenotype: a black and white case-control study Racial influence on the polycystic ovary syndrome phenotype: a black and white case-control study Gwinnett Ladson, M.D., a William C. Dodson, M.D., b Stephanie D. Sweet, M.D., a Anthony E. Archibong, Ph.D.,

More information

Metfornim and Pioglitazone in polycystic ovarian syndrome: A comparative study

Metfornim and Pioglitazone in polycystic ovarian syndrome: A comparative study Original Research Article Metfornim and Pioglitazone in polycystic ovarian syndrome: A comparative study Allanki Suneetha Devi 1, Jalem Anuradha 2* 1 Associate Professor, Department of Obstetrics and Gynecology,

More information

Case. 24 year old female presented to your office complaining of excess hair growth on her face and abdomen. Questions?

Case. 24 year old female presented to your office complaining of excess hair growth on her face and abdomen. Questions? Hirsutism Case 24 year old female presented to your office complaining of excess hair growth on her face and abdomen Questions? Started around puberty with gradual progression Irregular menstrual cycle

More information

Metformin and Pioglitazone in Polycystic Ovarian Syndrome: A Comparative Study

Metformin and Pioglitazone in Polycystic Ovarian Syndrome: A Comparative Study The Journal of Obstetrics and Gynecology of India (September-October 2012) 62(5):551 556 DOI 10.1007/s13224-012-0183-3 ORIGINAL ARTICLE Metformin and Pioglitazone in Polycystic Ovarian Syndrome: A Comparative

More information

PCOS What s new in Diagnosis & Treatment?

PCOS What s new in Diagnosis & Treatment? PCOS What s new in Diagnosis & Treatment? Roy Homburg Maccabi Medical Services and Barzilai Medical Centre, Ashkelon, Israel. Antalya, October, 2009 PCOS diagnosis - 1990 NIH criteria - Hyperandrogenism

More information

Screening non-classical 21-hydroxylase gene deficiency from patients diagnosed as polycystic ovary syndrome by gene assay HU Jie, JIAO Kai *

Screening non-classical 21-hydroxylase gene deficiency from patients diagnosed as polycystic ovary syndrome by gene assay HU Jie, JIAO Kai * Med J Chin PLA, Vol. 41, No. 3, March 1, 2016 227 21- [ ] (PCOS) 21- (NC-21OHD) 2014 2015 98 PCOS Ferriman-Gallway ( mf-g ) 3 mf-g 0~2 A 3~5 B 6 C30 DNA 5 CYP21A2 8 (ACTH) 30 98 PCOS 5 V281L/920-921insT(P1)

More information

POLYCYSTIC OVARIAN SYNDROME Laura Tatpati, MD Reproductive Endocrinology and Infertility. Based on: ACOG No. 108 Oct 2009; reaffirmed 2015

POLYCYSTIC OVARIAN SYNDROME Laura Tatpati, MD Reproductive Endocrinology and Infertility. Based on: ACOG No. 108 Oct 2009; reaffirmed 2015 POLYCYSTIC OVARIAN SYNDROME Laura Tatpati, MD Reproductive Endocrinology and Infertility Based on: ACOG No. 108 Oct 2009; reaffirmed 2015 NO DISCLOSURES PATIENT 26 years old presents with complaint of

More information

2-Hypertrichosis:- Hypertrichosis is the

2-Hypertrichosis:- Hypertrichosis is the Hirsutism And Virilization Hirsutism:- Is the development of androgen-dependent dependent terminal body hair in a woman in places in which terminal hair is normally not found, terminal body hairs are the

More information

Frank Gonzalez, M.D.,* Lillie Chang, M.D., Theresa Horab, R.N.,* Frank Z. Stanczyk, Ph.D., Kent Crickard, M.D.,* and Rogerio A. Lobo, M.D.

Frank Gonzalez, M.D.,* Lillie Chang, M.D., Theresa Horab, R.N.,* Frank Z. Stanczyk, Ph.D., Kent Crickard, M.D.,* and Rogerio A. Lobo, M.D. FERTILITY AND STERILITY VOL. 71, NO. 3, MARCH 1999 Copyright 1999 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Adrenal dynamic responses

More information

Dr Stella Milsom. Endocrinologist Fertility Associates Auckland. 12:30-12:40 When Puberty is PCO

Dr Stella Milsom. Endocrinologist Fertility Associates Auckland. 12:30-12:40 When Puberty is PCO Dr Stella Milsom Endocrinologist Fertility Associates Auckland 12:30-12:40 When Puberty is PCO Puberty or Polycystic Ovary Syndrome? Stella Milsom Endocrinologist Auckland DHB, University of Auckland,

More information

NIH Public Access Author Manuscript Fertil Steril. Author manuscript; available in PMC 2011 April 1.

NIH Public Access Author Manuscript Fertil Steril. Author manuscript; available in PMC 2011 April 1. NIH Public Access Author Manuscript Published in final edited form as: Fertil Steril. 2010 April ; 93(6): 1938 1941. doi:10.1016/j.fertnstert.2008.12.138. Prevalence of Hyperandrogenemia in the Polycystic

More information

Prevalence and hormonal profile of polycystic ovary syndrome in young Kashmiri women presenting with hirsutism: A hospital based study

Prevalence and hormonal profile of polycystic ovary syndrome in young Kashmiri women presenting with hirsutism: A hospital based study Original Article Prevalence and hormonal profile of polycystic ovary syndrome in young Kashmiri women presenting with hirsutism: A hospital based study Majid Jahangir, MD 1 Seema Qayoom, MD ² Peerzada

More information

Polycystic Ovarian Syndrome. Heidi Hallonquist, MD Concord Hospital Concord Obstetrics and Gynecology

Polycystic Ovarian Syndrome. Heidi Hallonquist, MD Concord Hospital Concord Obstetrics and Gynecology Polycystic Ovarian Syndrome Heidi Hallonquist, MD Concord Hospital Concord Obstetrics and Gynecology Outline Definition Symptoms Causal factors Diagnosis Complications Treatment Why are we talking about

More information

The Egyptian Journal of Hospital Medicine (January 2018) Vol. 70 (8), Page

The Egyptian Journal of Hospital Medicine (January 2018) Vol. 70 (8), Page The Egyptian Journal of Hospital Medicine (January 2018) Vol. 70 (8), Page 1278-1288 Anti-Mullerian Hormone: An Indicator for the Severity of Polycystic Ovarian Syndrome Yehia Abd-Elsalam Wafa 1, Mohamed

More information

Pregnancy in women with polycystic ovary syndrome: the effect of different phenotypes and features on obstetric and neonatal outcomes

Pregnancy in women with polycystic ovary syndrome: the effect of different phenotypes and features on obstetric and neonatal outcomes Pregnancy in women with polycystic ovary syndrome: the effect of different phenotypes and features on obstetric and neonatal outcomes Stefano Palomba, M.D., a Angela Falbo, M.D., a Tiziana Russo, M.D.,

More information

The excess in 2 5 mm follicles seen at ovarian ultrasonography is tightly associated to the follicular arrest of the polycystic ovary syndrome

The excess in 2 5 mm follicles seen at ovarian ultrasonography is tightly associated to the follicular arrest of the polycystic ovary syndrome Human Reproduction Vol.22, No.6 pp. 1562 1566, 2007 Advance Access publication on April 20, 2007 doi:10.1093/humrep/dem060 The excess in 2 5 mm follicles seen at ovarian ultrasonography is tightly associated

More information

Can high serum anti-müllerian hormone levels predict the phenotypes of polycystic ovary syndrome (PCOS) and metabolic disturbances in PCOS patients?

Can high serum anti-müllerian hormone levels predict the phenotypes of polycystic ovary syndrome (PCOS) and metabolic disturbances in PCOS patients? ORIGINAL ARTICLE http://dx.doi.org/1.5653/cerm.213.4.3.135 pissn 2233-8233 eissn 2233-8241 Clin Exp Reprod Med 213;4(3):135-14 Can high serum anti-müllerian hormone levels predict the phenotypes of polycystic

More information

SUPPLEMENTARY FIGURES

SUPPLEMENTARY FIGURES SUPPLEMENTARY FIGURES Supplementary Figure 1 Regional association plots for genome-wide significant PCOS signals. Dots represents individual SNP association P-values (on the log10 scale) in the 23andMe

More information

Polycystic ovary syndrome

Polycystic ovary syndrome Jon Havelock, MD, FRCSC Polycystic ovary syndrome Therapy for this reproductive and metabolic disorder remains focused on managing symptoms, including infertility caused by anovulation, and reducing long-term

More information

ORIGINAL ARTICLE Reproductive endocrinology. Submitted on February 4, 2011; resubmitted on April 29, 2011; accepted on May 9, 2011

ORIGINAL ARTICLE Reproductive endocrinology. Submitted on February 4, 2011; resubmitted on April 29, 2011; accepted on May 9, 2011 Human Reproduction, Vol.26, No.11 pp. 3123 3129, 2011 Advanced Access publication on September 16, 2011 doi:10.1093/humrep/der297 ORIGINAL ARTICLE Reproductive endocrinology Diagnosis of polycystic ovary

More information

16 YEAR-OLD OBESE FEMALE WITH OLIGOMENORRHEA

16 YEAR-OLD OBESE FEMALE WITH OLIGOMENORRHEA 16 YEAR-OLD OBESE FEMALE WITH OLIGOMENORRHEA Katie O Sullivan, MD Adult/Pediatric Endocrinology Fellow University of Chicago ENDORAMA Thursday, September 4th, 2014 Disclosures No financial interests. Will

More information

12/27/2013. Kristen Cain, MD FACOG Reproductive Medicine Institute Sanford Health, Fargo ND

12/27/2013. Kristen Cain, MD FACOG Reproductive Medicine Institute Sanford Health, Fargo ND Kristen Cain, MD FACOG Reproductive Medicine Institute Sanford Health, Fargo ND 7% of all women 18-45 Obesity 1/3 of all US women Incidence of PCOS is increasing with increase obesity Obesity Irregular

More information

Comparison of diabetes mellitus and insulin resistance screening methods for women with polycystic ovary syndrome

Comparison of diabetes mellitus and insulin resistance screening methods for women with polycystic ovary syndrome Comparison of diabetes mellitus and insulin resistance screening methods for women with polycystic ovary syndrome William W. Hurd, M.D., M.Sc., M.P.H., a Mohamed Y. Abdel-Rahman, M.D., a,d Salah A. Ismail,

More information

Clinical Study Hyperandrogenism Does Not Influence Metabolic Parameters in Adolescent Girls with PCOS

Clinical Study Hyperandrogenism Does Not Influence Metabolic Parameters in Adolescent Girls with PCOS International Endocrinology Volume 2012, Article ID 434830, 5 pages doi:10.1155/2012/434830 Clinical Study Hyperandrogenism Does Not Influence Metabolic Parameters in Adolescent Girls with PCOS Kim Forrester-Dumont,

More information

Clinical evaluation of hirsutism in South India

Clinical evaluation of hirsutism in South India International Journal of Research in Dermatology http://www.ijord.com Original Research Article DOI: http://dx.doi.org/10.18203/issn.2455-4529.intjresdermatol20184459 Clinical evaluation of hirsutism in

More information

Correlates of increased lean muscle mass in women with polycystic ovary syndrome

Correlates of increased lean muscle mass in women with polycystic ovary syndrome European Journal of Endocrinology (2009) 161 583 589 ISSN 0804-4643 CLINICAL STUDY Correlates of increased lean muscle mass in women with polycystic ovary syndrome E Carmina 1, E Guastella 2, R A Longo

More information

ORIGINAL ARTICLE Establishing the cut off values of androgen markers in the assessment of polycystic ovarian syndrome

ORIGINAL ARTICLE Establishing the cut off values of androgen markers in the assessment of polycystic ovarian syndrome Malaysian J Pathol 2018; 40(1) : 33 39 ORIGINAL ARTICLE Establishing the cut off values of androgen markers in the assessment of polycystic ovarian syndrome R N Dineshinee NADARAJA MBBS, Pavai STHANESHWAR

More information

JMSCR Vol 05 Issue 04 Page April 2017

JMSCR Vol 05 Issue 04 Page April 2017 www.jmscr.igmpublication.org Impact Factor 5.84 Index Copernicus Value: 83.27 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v5i4.228 Study of Cutaneous Manifestations of

More information

A practical approach to the diagnosis of polycystic ovary syndrome

A practical approach to the diagnosis of polycystic ovary syndrome American Journal of Obstetrics and Gynecology (2004) 191, 713 7 www.elsevier.com/locate/ajog CLINICAL OPINION A practical approach to the diagnosis of polycystic ovary syndrome R. Jeffrey Chang, MD Department

More information

Article PCOS in lesbian and heterosexual women treated with artificial donor insemination

Article PCOS in lesbian and heterosexual women treated with artificial donor insemination RBMOnline - Vol 17. No 3. 2008 398-402 Reproductive BioMedicine Online; www.rbmonline.com/article/3252 on web 22 July 2008 Article PCOS in lesbian and heterosexual women treated with artificial donor insemination

More information

Research Article Does Polycystic Ovary Syndrome Itself Have Additional Effect on Apelin Levels?

Research Article Does Polycystic Ovary Syndrome Itself Have Additional Effect on Apelin Levels? Obstetrics and Gynecology International, Article ID 536896, 4 pages http://dx.doi.org/10.1155/2014/536896 Research Article Does Polycystic Ovary Syndrome Itself Have Additional Effect on Apelin Levels?

More information

Differentiation between polycystic ovary syndrome and polycystic ovarian morphology by means of an anti-müllerian hormone cutoff value

Differentiation between polycystic ovary syndrome and polycystic ovarian morphology by means of an anti-müllerian hormone cutoff value ORIGINAL ARTICLE Korean J Intern Med 2017;32:690-698 Differentiation between polycystic ovary syndrome and polycystic ovarian morphology by means of an anti-müllerian hormone cutoff value Do Kyeong Song,

More information

Prof.Dr. Nabil Lymon Head of Internal Medicine Department

Prof.Dr. Nabil Lymon Head of Internal Medicine Department By Prof.Dr. Nabil Lymon Head of Internal Medicine Department Definitions: Hirsutism: Is the presence of terminal hair in androgendependent sites where hair does not normally grow in women. This hair growth

More information

European Journal of Endocrinology (2002) ISSN

European Journal of Endocrinology (2002) ISSN European Journal of Endocrinology (2002) 147 473 477 ISSN 0804-4643 CLINICAL STUDY A comparison between the effects of low dose (1 mg) and standard dose (250 mg) ACTH stimulation tests on adrenal P450c17a

More information

Study of clinical presentation in cases of Polycystic Ovarian Syndrome in rural population

Study of clinical presentation in cases of Polycystic Ovarian Syndrome in rural population Original article: Study of clinical presentation in cases of Polycystic Ovarian Syndrome in rural population 1Dr Shalini Kanotra, 2 Dr Nikita Singh*, 3 Dr V B Bangal 1 Associate Professor, OBGY Department,

More information

Abstract. Introduction. RBMOnline - Vol 10. No Reproductive BioMedicine Online; on web 15 November 2004

Abstract. Introduction. RBMOnline - Vol 10. No Reproductive BioMedicine Online;   on web 15 November 2004 RBMOnline - Vol 10. No 1. 2005 100-104 Reproductive BioMedicine Online; www.rbmonline.com/article/1484 on web 15 November 2004 Article Metformin monotherapy in lean women with polycystic ovary syndrome

More information

Effect of troglitazone on endocrine and ovulatory performance in women with insulin resistance related polycystic ovary syndrome

Effect of troglitazone on endocrine and ovulatory performance in women with insulin resistance related polycystic ovary syndrome FERTILITY AND STERILITY VOL. 71, NO. 2, FEBRUARY 1999 Copyright 1999 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Effect of troglitazone

More information

New PCOS guidelines: What s relevant to general practice

New PCOS guidelines: What s relevant to general practice New PCOS guidelines: What s relevant to general practice Dr Michael Costello Fertility Specialist IVF Australia UNSW Royal Hospital for Women Sydney How do we know if something is new? Louvre Museum, Paris

More information

Objectives 1. Be able to describe the classic presentation and diagnostic criteria 2. Be able to explain long-term health concerns associated with the diagnosis 3. Understand what basic treatment options

More information

Gonadotrophin treatment in patients with Polycystic Ovary Syndrome

Gonadotrophin treatment in patients with Polycystic Ovary Syndrome Int. J. Adv. Res. Biol. Sci. (218). 5(4): 95-99 International Journal of Advanced Research in Biological Sciences ISSN: 2348-869 www.ijarbs.com DOI: 1.22192/ijarbs Coden: IJARQG(USA) Volume 5, Issue 4-218

More information

Metformin Therapy Decreases Hyperandrogenism and Ovarian Volume in Women with Polycystic Ovary Syndrome

Metformin Therapy Decreases Hyperandrogenism and Ovarian Volume in Women with Polycystic Ovary Syndrome IJMS Vol 36, No 2, June 2011 Original Article Metformin Therapy Decreases Hyperandrogenism and Ovarian Volume in Women with Polycystic Ovary Syndrome Marzieh Farimani Sanoee 1, Nosrat Neghab 1, Soghra

More information

Female androgen profiles by MS for PCOS patients. CS Ho APCCMS 2010, Hong Kong 14 January 2010

Female androgen profiles by MS for PCOS patients. CS Ho APCCMS 2010, Hong Kong 14 January 2010 Female androgen profiles by MS for PCOS patients CS Ho APCCMS 2010, Hong Kong 14 January 2010 873 women with increased serum androgens Androgen-secreting neoplasms 0.2% Classical CAH 0.6% Non-classical

More information

Diagnostic features of polycystic ovary syndrome

Diagnostic features of polycystic ovary syndrome REVIEW article Diagnostic features of polycystic ovary syndrome 3 N Barday-Karbanee, MB ChB, DTM&H, BSc Hons (Reprod Biol) Berg Medicross, Newville, Johannesburg T I Siebert, MMed (O&G), FCOG M H Botha,

More information

Academic Sciences. Asian Journal of Pharmaceutical and Clinical Research

Academic Sciences. Asian Journal of Pharmaceutical and Clinical Research Academic Sciences Asian Journal of Pharmaceutical and Clinical Research Vol 5, Issue 3, 202 ISSN - 0974-244 Research Article A COMPARATIVE STUDY ON THE EFFECTIVENESS OF SINGLE AND COMBINATION THERAPIES

More information

Body mass index and ovarian function are associated with endocrine and metabolic abnormalities in women with hyperandrogenic syndrome

Body mass index and ovarian function are associated with endocrine and metabolic abnormalities in women with hyperandrogenic syndrome European Journal of Endocrinology (2008) 158 711 719 ISSN 0804-4643 CLINICAL STUDY Body mass index and ovarian function are associated with endocrine and metabolic abnormalities in women with hyperandrogenic

More information

PCOS and Obesity DUB is better treated by OCPs

PCOS and Obesity DUB is better treated by OCPs PCOS and Obesity DUB is better treated by OCPs Dr. Ritu Joshi Senior consultant Fortis escorts Hospital, Jaipur Chairperson Family welfare com. FOGSI (20092012) Vice President FOGSI 2014 Introduction One

More information